Drug intelligence / Profile preview

Z-007

Development stage: Preclinical
Lead developer: TherAquila
Modality: DNA Therapeutics → Nucleic Acid Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Intraperitoneal

Overview

Z-007 is a novel native backbone RNA/DNA hybrid designed to co-stimulate Toll-like Receptors 7, 8, and 9 (TLR7/8/9). It is delivered using a non-inflammatory Lipid Nanoparticle (LNP) to avoid inducing neutralizing antibodies. Z-007 induces remarkably high IFN-alpha secretion and promotes antitumor immunity without a systemic inflammatory response, making it a promising candidate for human cancer immunotherapy. Preclinical studies have shown that Z-007 induces tumor regression in mouse models and high IFN-alpha induction in human cells, mice, and monkeys, with no apparent toxicity.

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on Z-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z-007.

Explore the full profile